Pityriasis Rubra Pilaris Treated with Infliximab.
- Author:
Joon Seok CHOI
1
;
Ji Hoon KIM
;
Jeong Hwan YUN
;
Hong Kyu KANG
;
Jin Ok BAEK
;
Jong Rok LEE
;
Joo Young ROH
Author Information
1. Department of Dermatology, Gachon University School of Medicine, Gil Medical Center, Incheon, Korea. jyroh1@gilhospital.com
- Publication Type:Case Report
- Keywords:
Anti-TNF-alpha monoclonal antibody;
Infliximab;
Pityriasis rubra pilaris
- MeSH:
Acitretin;
Antibodies, Monoclonal;
Biological Agents;
Emollients;
Humans;
Immunosuppressive Agents;
Methotrexate;
Phototherapy;
Pityriasis;
Pityriasis Rubra Pilaris;
Retinoids;
Skin Diseases, Papulosquamous;
Infliximab
- From:Korean Journal of Dermatology
2012;50(11):982-986
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Pityriasis rubra pilaris (PRP) is a chronic papulosquamous disorder of unknown etiology, which may pose therapeutic challenges. There is currently no universally effective treatment for PRP, and some cases are resistant to multiple topical and systemic therapies. Systemic retinoids, methotrexate, several immunosuppressive agents and phototherapy have all been used with varying degrees of success. Recently, a few reports have appeared in the literature, concerning the use of biologics in combination therapies and/or in refractory PRP cases. We report a case of PRP similar to type II with juvenile onset, which was recalcitrant to traditional topical and systemic therapy. He was successfully treated with anti-TNF-alpha monoclonal antibody, infliximab. The patient showed resolution with minimal disease activity, and was maintained on acitretin and emollients. The response to infliximab in our patient and in the previously reported cases confirms a role of anti-TNF-alpha therapy as an effective option in the treatment of PRP.
